Expertise in
10
conditions

Dr. Amber R. Khan

Rheumatology
Office
2222 Greenhouse Rd Ste 1300, 
Houston, TX 
Accepting New Patients
Referral may be required
Before you request
Expertise in
10
conditions
Office
2222 Greenhouse Rd Ste 1300, 
Houston, TX 

Overview

Amber Khan is a Rheumatologist practicing medicine in Houston, Texas.

Dr. Khan is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), Rheumatoid Lung Disease, and Rheumatoid Pneumoconiosis.

She is actively involved in clinical research, participating in 10 clinical trials. Dr. Khan is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in OH

Hospital Affiliations

Memorial Hermann Katy Hospital

Languages Spoken

English
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Office
2222 Greenhouse Rd Ste 1300, Houston, TX 77084

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis
A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required
Before you request

Baylor Medicine Rheumatology

7200 Cambridge St, 
Houston, TX 
 (18.2 miles away)
713-798-3390
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Jasvinder Singh is a Rheumatologist practicing medicine in Houston, Texas. Dr. Singh is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Gout, Arthritis, Rheumatoid Arthritis (RA), Knee Replacement, and Hip Replacement. Dr. Singh is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required
Before you request
6410 Fannin St, Ste 450, 
Houston, TX 
 (17.5 miles away)
832-325-7191
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

John Reveille is a Rheumatologist practicing medicine in Houston, Texas. Dr. Reveille is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ankylosing Spondylitis, Arthritis, Axial Spondyloarthritis (AxSpA), and Scleroderma. Dr. Reveille is currently accepting new patients.

Expertise in
8
conditions
Dr. Shervin Assassi
Rheumatology
Expertise in
8
conditions
Dr. Shervin Assassi
Rheumatology
Referral required
Before you request
6410 Fannin St, Ste 450, 
Houston, TX 
 (17.5 miles away)
713-486-3100
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients

Shervin Assassi is a Rheumatologist practicing medicine in Houston, Texas. Dr. Assassi is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Localized Scleroderma, and Pulmonary Fibrosis. Dr. Assassi is currently accepting new patients.

Frequently Asked Questions about Dr. Amber R. Khan

How do I make an appointment with Dr. Amber R. Khan?

You can book an appointment with Dr. Amber R. Khan by calling their office at 281-851-7088. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amber R. Khan a top-rated expert for Ankylosing Spondylitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amber R. Khan is classified as an Distinguished expert for Ankylosing Spondylitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amber R. Khan specialize in?

While Dr. Amber R. Khan is a Rheumatology, they have specific expertise in Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), and Rheumatoid Lung Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Amber R. Khan accept my insurance?

Dr. Amber R. Khan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 281-851-7088 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khan's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile